Servier Germany will start to co-promote Novartis’ potential blockbuster Entresto® (Sacubitril/Valsartan) used in cardiovascular diseases in Germany from November 1st 2017 onwards.
Servier was chosen for “its excellent knowledge and contacts in the field of cardiovascular diseases,” said Dr. Rüdiger Merkel, Head Cardio-Metabolic Franchise from Novartis Germany in an internal joined meeting with Servier and Novartis in Alpbach, Tirol/Austria. “Together, we will be able to inform cardiologists and GPs even in a more targeted way”, he added.
“Servier Germany is very pleased about this cooperation, as this agreement once again underscores our proven high expertise in the field of cardiovascular diseases”, said Oliver Kirst, General Manager of Servier Germany. “As still demonstrated within our ongoing cooperation with Boehringer Ingelheim, our teams are also fully committed to promote Entresto®“, he added.
